Nurix Therapeutics (NRIX) Accumulated Expenses (2019 - 2026)

At the end of FY2025 (ended Nov 30, 2025), Accumulated Expenses at Nurix Therapeutics came in at $54.85 million, up 44.4% from FY2024.

• Accumulated Expenses has now increased for six consecutive fiscal years, with a five-year compound annual growth rate of 45.8% (FY2020 to FY2025).
• In earlier fiscal years, Accumulated Expenses was $37.99 million in FY2024 (+52.2%), $24.97 million in FY2023 (+11.3%), $22.43 million in FY2022 (+54.2%) and $14.55 million in FY2021 (+74.7%).
• The fiscal Q3 2026 figure marks the highest quarterly Accumulated Expenses in data going back to fiscal Q4 2019.
• Compared with a year earlier, Accumulated Expenses has increased for 13 straight quarters, with growth averaging 45.9% over the last eight quarters.
• The best year-over-year quarter for Accumulated Expenses over five years was fiscal Q2 2022 (growth of 157.0%); the worst was fiscal Q2 2023 (a decline of 8.3%).
• Per Business Quant data, NRIX's Accumulated Expenses in the three fiscal quarters before Q3 2026 was $43.27 million (Q2 2026), $59.95 million (Q1 2026) and $54.85 million (Q4 2025).